Solicitation Number: 75N95025Q00247

Title: Covalent Screening Library of Small Molecules (500 from Sulfamoyl Fluorides set and 500 from Cyanamides set)

Classification Code: 6810 - CHEMICALS

NAICS Code:  32599-ALL OTHER MISCELLANEOUS CHEMICAL PRODUCT AND PREPARATION MANUFACTURING

Size Standard: 650 employees

Description:

This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement.

This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement, to determine the method of acquisition, and availability of domestic sources manufactured in the United States in sufficient and reasonably available commercial quantities and of a satisfactory quality.  It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.  Responses will not be considered as proposals or quotes.  No award will be made as a result of this notice.  The Government will NOT be responsible for any costs incurred by the respondents to this notice.  This notice is strictly for research and information purposes only. Small businesses are encouraged to respond.

For equipment/supply requirements, responses must include the place of manufacturing (i.e. address if supply/equipment is a domestic end product and include country of manufacturing). For equipment/supply requirements, small businesses must also address the size status of the manufacturer under the applicable NAICS code (i.e. address Non-Manufacturer Rule).

Background: The current DPI compound collection notably lacks a collection of custom covalent libraries. Covalent inhibitors offer several advantages, including the ability to target proteins considered undruggable in live cells, the development of novel affinity-based probes, enhanced potency, and prolonged duration of action. This approach is particularly appealing in both medicinal chemistry and chemical biology research. Acquiring these compounds from Enamine is imperative to development of a focused, custom covalent library that spans a broader and more diverse chemical space. Screening compounds with reactive warheads has emerged as a promising strategy to both discover and validate new targets, and to identify hits for targets that are otherwise considered undruggable. Acquiring such a library will provide complete access to resources for DPI groups, thereby advancing their programs and enhancing or complementing their quantitative high-throughput screening (qHTS) campaigns.

Purpose and Objectives: NCATS ETB is looking to expand its covalent screening library of small molecules. Adding diversity to chemical libraries is imperative to our operation, as we screen a variety of targets against these in-house collections.

The current DPI compound collection notably lacks a collection of custom covalent libraries. Covalent inhibitors offer several advantages, including the ability to target proteins considered undruggable in live cells, the development of novel affinity-based probes, enhanced potency, and prolonged duration of action. This approach is particularly appealing in both medicinal chemistry and chemical biology research. Acquiring these compounds is imperative to development of a focused, custom covalent library that spans a broader and more diverse chemical space. Screening compounds with reactive warheads has emerged as a promising strategy to both discover and validate new targets, and to identify hits for targets that are otherwise considered undruggable. Acquiring such a library will provide complete access to resources for DPI groups, thereby advancing their programs and enhancing or complementing their quantitative high-throughput screening (qHTS) campaigns.

Project requirements: Please see PURCHASE DESCRIPTION attached to this posting.

Salient characteristics:

1. Small molecules must have validated biological and pharmacological activities.
2. Must be available for high-throughput screening (HTS) and high-content screening (HCS).
3. Must come with detailed biological and chemical information with LC/MS and/or NMR reports to ensure high quality.
4. Guaranteed to have a purity of >90% (accuracy +/-5%)  that is to be confirmed by NMR and/or LCMS spec

Anticipated period of performance: Within 6 weeks after the purchase order is received.

Capability statement /information sough